A large new study suggests that clopidogrel, a widely used blood-thinning medicine, may protect people with heart disease better than aspirin over the long term.
The research, published in The Lancet, raises questions about the long-standing practice of using aspirin as the main lifelong treatment for many people with coronary artery disease.
Coronary artery disease, often called CAD, develops when fatty deposits build up inside the arteries that supply blood to the heart. As these arteries become narrower, the heart receives less oxygen-rich blood.
This increases the risk of heart attacks, strokes, and other serious health problems, making CAD one of the leading causes of death worldwide.
After a heart attack, a stent procedure, or another major heart problem, patients are usually prescribed medicines that reduce the chance of blood clots forming inside the arteries.
Aspirin has been the standard long-term treatment for many years because it lowers the risk of future heart attacks and strokes and is inexpensive and widely available.
Researchers wanted to find out whether clopidogrel could provide even better protection.
To answer this question, they combined results from seven high-quality clinical trials involving nearly 29,000 people with coronary artery disease. Looking at many studies together gives scientists a clearer picture than relying on a single trial alone.
The analysis found that people taking clopidogrel had a 14% lower risk of major cardiovascular events, including heart attacks and strokes, compared with people taking aspirin. This suggests that clopidogrel may provide stronger long-term protection for people already living with heart disease.
Bleeding is one of the biggest concerns with medicines that reduce blood clotting. However, the researchers found that patients taking clopidogrel did not have a higher risk of major bleeding than those taking aspirin. This means the extra protection was not linked to greater safety concerns in the studies included in the analysis.
The research included a wide range of patients, including people who had coronary stents and those who had experienced serious heart events. The team also examined whether genetic differences or other medical factors changed the results. Even among people who were expected to respond less well to clopidogrel, the medicine still performed better than aspirin overall.
Because both medicines are already available in many countries, the findings could have an important impact on future treatment guidelines. If additional research confirms these results, doctors may increasingly choose clopidogrel instead of aspirin for long-term care in people with established coronary artery disease.
The researchers say more studies are still needed to examine the cost-effectiveness of clopidogrel and to confirm its benefits in even larger and more diverse groups of patients.
Until treatment guidelines are updated, people should continue taking the medicine prescribed by their doctor and should not switch between aspirin and clopidogrel without medical advice.
If you care about heart health, please read studies about the best time to take vitamins to prevent heart disease, and calcium supplements could harm your heart health.
For more health information, please see recent studies that blackcurrants can reduce blood sugar after meal and results showing how drinking milk affects risks of heart disease and cancer.
Copyright © 2026 Knowridge Science Report. All rights reserved.
